ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2012
EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 72 citations in OpenAlex.
- Mapping cancer biology in space: applications and perspectives on spatial omics for oncology.Molecular cancer · 2024Review
- Effect of Antigen Retrieval on Genomic DNA From Immunodissected Samples.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2022Article
- Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza.European respiratory review : an official journal of the European Respiratory Society · 2017Review
- Quantitative proteomics analysis of mitochondrial proteins in lung adenocarcinomas and normal lung tissue using iTRAQ and tandem mass spectrometry.American journal of translational research · 2017Article
- Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience.Archives of pathology & laboratory medicine · 2016Article
- Article
- HistoMosaic Detecting KRAS G12V Mutation Across Colorectal Cancer Tissue Slices through in Situ PCR.Analytical chemistry · 2016Article
- Necessity of Microdissecting Different Tumor Components in Pulmonary Tumor Pyrosequencing.BioMed research international · 2016Article
- Article
- The Utilization of Cytologic Fine-Needle Aspirates of Lung Cancer for Molecular Diagnostic Testing.Journal of pathology and translational medicine · 2015Review
- Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.BMC cancer · 2015Article
- ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens.Journal of cancer research and clinical oncology · 2015Article
- Network-Based Logistic Classification with an Enhanced L 1/2 Solver Reveals Biomarker and Subnetwork Signatures for Diagnosing Lung Cancer.BioMed research international · 2015Article
- Molecular testing guidelines for lung adenocarcinoma: Utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples.CytoJournal · 2014Article
- [Molecular pathological diagnosis in cytopathology of non-small-cell lung cancer. Standardization of specimen processing].Der Pathologe · 2013Review
- Ocular metastasis of lung adenocarcinoma with ELM4-ALK translocation: A case report with a review of the literature.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society · 2013Article
- Microfluidic sample preparation for diagnostic cytopathology.Lab on a chip · 2013Review
- EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.Journal of clinical pathology · 2013Review
- Article
- Microfluidic purification and concentration of malignant pleural effusions for improved molecular and cytomorphological diagnostics.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
The discovery of activating mutations in EGFR and KRAS in a subset of lung adenocarcinomas was a major advance in our understanding of lung adenocarcinoma biology, and has led to groundbreaking studies that have demonstrated the efficacy of tyrosine kinase inhibitor therapy. Fine-needle aspirates and other cytologic procedures have become increasingly popular for obtaining diagnostic material in lung carcinomas. However, frequently the small amount of material or sparseness of tumor cells obtained from cytologic preparations limit the number of specialized studies, such as mutation analysis, that can be performed. In this study we used laser capture microdissection to isolate small numbers of tumor cells to assess for EGFR and KRAS mutations from cell block sections of 19 cytology samples from patients with known lung adenocarcinomas. We compared our results with previous molecular assays that had been performed on either surgical or cytology specimens as part of the patient's initial clinical work-up. Not only were we able to detect the identical EGFR or KRAS mutation that was present in the patient's prior molecular assay in every case, but we were also able to consistently detect the mutation from as few as 50 microdissected tumor cells. Furthermore, isolating a more pure population of tumor cells resulted in increased sensitivity of mutation detection as we were able to detect mutations from laser capture microdissection-enriched cases where the tumor load was low and traditional methods of whole slide scraping failed. Therefore, this method can not only significantly increase the number of lung adenocarcinoma patients that can be screened for EGFR and KRAS mutations, but can also facilitate the use of cytologic samples in the newly emerging field of molecular-based personalized therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.